Regeneron Pharmaceuticals vs Teva Pharmaceutical Industries
REGN and TEVA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How REGN and TEVA compare
Regeneron Pharmaceuticals is the larger company, worth 2.0 times as much as Teva Pharmaceutical Industries ($99.2B against $49.4B).
On earnings, Regeneron Pharmaceuticals is cheaper: it trades at 21.2× trailing earnings, against 70.7× for Teva Pharmaceutical Industries.
Regeneron Pharmaceuticals grew revenue faster over the last twelve months (18.6% versus −15.2% for Teva Pharmaceutical Industries).
Regeneron Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 28.5% compared with 5.0% at Teva Pharmaceutical Industries.
Regeneron Pharmaceuticals pays a dividend yielding 0.39%; Teva Pharmaceutical Industries does not pay one.
Regeneron Pharmaceuticals scores higher on the StockData Score (16 against 7 for Teva Pharmaceutical Industries), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | REGN | TEVA |
|---|---|---|
| Size and price | ||
| Market cap | $99.2B | $49.4B |
| Share price | $959.41 | $42.40 |
| Change, 1 year | 46.5% | 76.9% |
| Change, 5 years | 47.0% | 377% |
| Beta (5Y) | 0.62 | 0.98 |
| Employees | 15K | 34K |
| StockData Score | ||
| Total score | 16 (better) | 7 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 2 |
| Performance score | 4 | 4 |
| Health score | 6 (better) | 1 |
| Dividend score | 3 (better) | 0 |
| Valuation | ||
| P/E | 21.2× (better) | 70.7× |
| P/S | 5.9× | 3.5× (better) |
| P/B | 3.0× (better) | 6.4× |
| EV/EBITDA | 17.1× (better) | 19.4× |
| P/FCF | 25.9× (better) | 36.7× |
| PEG | 7.66 | – |
| FCF yield | 3.9% (better) | 2.7% |
| Fair value | $890.93 | $19.87 |
| Margin of safety | −7.7% (better) | −113% |
| Growth | ||
| Revenue growth (TTM) | 18.6% (better) | −15.2% |
| Revenue growth, 5Y average | 11.0% (better) | 0.71% |
| Net income growth (TTM) | 5.2% | – |
| EPS growth (TTM) | 8.4% | – |
| EPS growth, 5Y average | 6.3% | – |
| Profitability | ||
| Gross margin | – | 64.4% |
| Operating margin | 28.8% (better) | 11.4% |
| Net margin | 28.5% (better) | 5.0% |
| FCF margin | 22.6% (better) | 9.6% |
| Return on equity | 14.9% (better) | 9.7% |
| Return on invested capital | 16.3% | 23.0% (better) |
| Financial health | ||
| Debt / equity | 0.06 (better) | 0.58 |
| Net debt / EBITDA | −1.36 | 0.33 (better) |
| Interest coverage | 104× | – |
| Current ratio | 3.35 (better) | 0.88 |
| Altman Z-score | 7.84 (better) | 0.86 |
| Piotroski F-score | 5 | 8 (better) |
| Dividends and buybacks | ||
| Dividend yield | 0.39% | – |
| Payout ratio | 8.0% | – |
| Buyback yield | 2.0% | – |
| Shareholder yield | 2.4% (better) | 0.00% |
| Ownership | ||
| Held by institutions | 88.5% | – |
| Held by insiders | 3.7% | 0.43% |
| Insider net buying, 12 months | −$57.4M (better) | −$108M |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 2.2% | 2.4% |
Go deeper
- REGN stock overview
- REGN income statement
- REGN valuation and score
- TEVA stock overview
- TEVA income statement
- TEVA valuation and score
Other comparisons
For information only, not investment advice. Check the source filings before relying on any figure.